FDA Mulls National Priority Vouchers for Two Potential Merck Blockbusters: Report

The FDA is reportedly considering awarding Commissioner’s National Priority Vouchers to two investigational Merck drugs—enlicitide decanoate, an oral PCSK9 inhibitor that reduced LDL-C by 55.8% versus placebo at 24 weeks, and sacituzumab tirumotecan, an ADC that cut risk of progression or death by 51% versus chemotherapy in Phase III OPtiTROP-Lung04—which would compress review windows from ~10–12 months to 1–2 months. Merck has not yet filed approval applications; Reuters cites expected submission timing of April for enlicitide decanoate and November for sacituzumab tirumotecan, and notes a $700M Blackstone funding deal and analyst forecasts valuing the ADC as a potential multi-billion to ~$10B franchise. The reports are unconfirmed by HHS, making near-term regulatory certainty speculative but potentially materially positive for Merck’s growth prospects if vouchers are granted.

Analysis

Market structure: If the FDA awards Commissioner’s National Priority Vouchers to Merck (MRK) candidates, MRK is the primary beneficiary with 1–2 quarter acceleration to launch that could translate into a first‑in‑class premium. Enlicitide (oral PCSK9) threatens incumbents in injectable PCSK9 (AMGN, REGN) and statin adjuncts—expect 5–20% market‑share erosion for injectables over 3–5 years and downward pressure on prices as payers push step therapy. ADC supply constraints and complex COGS keep initial gross margins lower (20–30%) for sacituzumab relative to small molecules; cross‑asset effects: MRK equity outperformance, modest tightening in its credit spreads (~5–15bps), and near‑term IV compression on MRK options around regulatory milestones.

Risk assessment: High‑impact tails include no‑voucher (30–40% chance), regulator-requested additional trials (20–30%), or payer reimbursement delays that cut peak sales 30–50%. Immediate risk window: days (market rumors); short term: April 2026 (enlicitide filing) and Nov 2026 (sacituzumab filing) where newsflow will spike; long term: 2027–2030 commercialization and payer carve‑outs. Hidden dependencies: voucher awards can be granted without applications (J&J precedent), reducing signal value; Blackstone funding for the ADC implies milestone‑linked dilution or revenue share that could cap upside.

Trade implications: Establish a tactical 2–3% long MRK equity exposure now to capture newsflow; layer with a hedged call spread (buy 12–18‑month ATM calls, sell 30–40% OTM calls) sized as 0.5–1% notional to cap downside. Pair trade: long MRK / short AMGN equal notional 1–2% to play oral PCSK9 disruption; add small put protection on MRK around filings (buy Apr 2026 1–3% OTM puts) to limit headline risk. Rotate modestly away (underweight) from small‑cap biotech exposed to cholesterol markets and overweight large integrated pharmas with manufacturing scale.

Contrarian angles: Consensus underestimates payer friction—even with a voucher, reimbursement and guideline changes can lag by 6–18 months, so first‑year revenue could be 30–60% of peak consensus. The market may overpay for the narrative (Wegovy parallel) while underpricing ADC manufacturing and label complexity; prefer options and pair trades over outright leverage. Historical parallels: prior vouchers produced big equity pops but mixed commercial outcomes—trade for catalyst windows, not permanent holds.

Key Decisions for Investors

• Establish a 2–3% long position in MRK now to capture potential voucher/filing upside, and plan to add up to +1% on a confirmed FDA voucher announcement; target holding period through Dec 2026 (cover if shares rally >15%).
• Implement a hedged options sleeve on MRK: buy a 12–18 month ATM call / sell a 30–40% OTM call (call spread) sized at 0.5–1% notional to monetize upside while capping cost; buy limited Apr 2026 1–3% OTM puts (protective) ahead of the enlicitide filing.
• Enter a pair trade: long MRK (1–2%) / short AMGN (1–2%) to express displacement risk to injectables; trim both legs if relative moves exceed 15% or if payer reimbursement guidance is published.
• Reduce exposure to small‑cap PCSK9 and niche lipid players by 2–5% of portfolio weight and rotate into large pharma names with on‑shore manufacturing (JNJ, MRK) to benefit from domestic manufacturing preferences over the next 6–18 months.
• Do not size unhedged long bets >3% on sacituzumab until after the Nov 2026 filing and initial label/payer signals; consider buying 9–12 month call spreads only after positive FDA acceptance to avoid binary approval risk.